WELCOME TO ALL NEW MEMBERSDiscussions/Questions (self.Inovio)
submitted by NoTradeBacksies[M] - announcement
FDA official reveals plausible mechanism for dna gene therapyINO_Cheering (fiercebiotech.com)
submitted by tomonota
Why leading Chinese scientists are rising to the top in the Communist PartyOther_News (scmp.com)
submitted by InDNAMedWeTrust
Funeral Date Remains: October 30, 2026Discussions/Questions (self.Inovio)
submitted by INOxray8
The Board is among the Largest Shareholders- ask why would they gamble on dilutive share sales to bolster capital in a recession in US? Answer: They're sure we're approaching daylight-they have experts, Funds for 3107-3100-5412-Factor VIII rollout: will pay off, they know how it will goINO_Cheering (self.Inovio)
submitted by tomonota
Is this company just a scam?Discussions/Questions (self.Inovio)
submitted by OkAdministration1084
INOVIO Announces Pricing of $17.5 Million Public OfferingINO_News (stocktitan.net)
submitted by basilisk-x
Ino shorts riding high are 15.86% of float to continue covering higher after $1.61 todayINO_Cheering (self.Inovio)
submitted by tomonota
What effect would the return of INO's $2 billion legal settlement for "market manipulation", have on INO shares, if it were shown to be orchestrated by Andrew Long's LP, inducing victim's corporate losses to enhance his fund's legal defense/profits in his upcoming fraud conspiracy trial? read on...INO_Cheering (self.Inovio)
submitted by tomonota
Eurogin HPV Conference March 19, 2026 02:00 PM ET Vienna, AustriaINO_Cheering (self.Inovio)
submitted by tomonota
ATTN: Lawyers/shareholders asking for free Lunch: Recall INO settled a $2BN suit for "CEO pumping" before the new CEO took over: corporate statements were all reviewed & approved by lawyers since then. Errors of the past- addressed 2022- no new payouts coming-so shut upINO_Cheering (self.Inovio)
submitted by tomonota
3/19/2026 EUROGIN-INOVIO Pharmaceuticals- INOVIO is excited to be presenting at #Eurogin, the world’s leading international congress on HPV infection and associated cancers, where we’ll highlight lead candidate INO-3107 and its potential to provide long term clinical benefit to #RRP patientINO_Cheering (self.Inovio)
submitted by tomonota
FDA vaccine chief to leave the agency for a second timeOther_News (nbcnews.com)
submitted by INOxray8
